These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21882119)

  • 21. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.
    Bonanni P; Cohet C; Kjaer SK; Latham NB; Lambert PH; Reisinger K; Haupt RM
    Vaccine; 2010 Jul; 28(30):4719-30. PubMed ID: 20451636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The contribution of social medicine to vaccination in Austria].
    Kunze M
    Wien Med Wochenschr; 1998; 148(8-9):191-7. PubMed ID: 9677675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.
    Peter G; des Vignes-Kendrick M; Eickhoff TC; Fine A; Galvin V; Levine MM; Maldonado YA; Marcuse EK; Monath TP; Osborn JE; Plotkin S; Poland GA; Quinlisk MP; Smith DR; Sokol M; Soland DB; Whitley-Williams PN; Williamson DE; Breiman RF
    Pediatrics; 1999 Oct; 104(4 Pt 1):942-50. PubMed ID: 10506239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.
    Moro PL; Haber P; McNeil MM
    Expert Rev Vaccines; 2019 Oct; 18(10):1091-1101. PubMed ID: 31580725
    [No Abstract]   [Full Text] [Related]  

  • 27. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J; Mackiewicz A
    Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Communicating vaccine safety during the development and introduction of vaccines.
    Kochhar S
    Curr Drug Saf; 2015; 10(1):55-9. PubMed ID: 25859676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine safety: current systems and recent findings.
    Wharton M
    Curr Opin Pediatr; 2010 Feb; 22(1):88-93. PubMed ID: 19952750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS; Griffiths E
    Mol Biotechnol; 2001 Feb; 17(2):143-9. PubMed ID: 11395863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A global perspective on vaccine safety.
    Duclos P
    Vaccine; 2004 May; 22(15-16):2059-63. PubMed ID: 15121323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
    Patel MM; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development pathway for biodefense vaccines.
    Barrett AD; Beasley DW
    Vaccine; 2009 Nov; 27 Suppl 4():D2-7. PubMed ID: 19837280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.
    Lopalco PL; DeStefano F
    Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.